The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy

Transfusion

Volumn 38, Issue 9, 1998, Pages 810-816

  Brown, P ^a   Rohwer, R G ^b,c   Dunstan, B C ^d   MacAuley, C ^d   Gajdusek, D C ^e   Drohan, W N ^f  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Medical Research Service

^c UNIVERSITY OF MARYLAND   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Laboratory of CNS Studies

^f HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CALCIUM ION; FIBRINOGEN; IMMUNOGLOBULIN; PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLOOD DONOR; BRAIN SPONGIOSIS; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; CRYOPRECIPITATE; FEMALE; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HAMSTER; HUMAN; HUMAN TISSUE; MOUSE; PLASMA; SCRAPIE AGENT; VIRUS INFECTIVITY;

EID: 3543092761     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1998.38998408999.x     Document Type: Article

References (21)

1. Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995;2:472-7.
2. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983;41:154-61.
3. Vandersande J. Current approaches to the preparation of plasma fractions. In: Goldstein J, ed. Biotechnology of blood. Boston: Buttenvorth-Heinemann, 1991;165-76.
4. Reed LJ, Muench H. A simple method of estimating fifty percent end points. Amer J Hyg 1938;27:493-7.
5. Tateishi J, Ohta AM, Koga M, et al. Transmission of chronic spongiform encephalopathy with kuru plaques from humans to small rodents. Ann Neurol 1979;5:581-4.
6. Doh-ura K, Tateishi J, Kitamoto T, et al. Creutzfeldt-Jakob disease patients with congophilic plaques have the missense variant prion protein common to Gerstmann-Sträussler syndrome. Ann Neurol 1990;27:121-6.
7. Mould DL, Dawson A McL, Smith W. Scrapie in mice. The stability of the agent to various suspending media, pH and solvent extraction. Res Vet Sci 1965;151-4.
8. Hartley EG. Action of disinfectants on experimental mouse scrapie. Nature 1967;213:1135.
9. Gibbs CJ Jr, Gajdusek DC, Morris JA. Viral characteristics of the scrapie agent in mice. In: Gajdusek DC, Gibbs CJ Jr, Alpers M, eds. Slow, latent, and temperate virus infections, NINDB Monograph no. 2, PHS Publication no. 1378. Washington, DC: US Government Printing Office, 1965:195-202.
10. Clarke MC, Haig DA. Presence of the transmissible agent of scrapie in the serum of affected mice and rats. Vet Rec 1967;80:504.
11. Tamai Y, Kojuma H, Kitajima R, et al. Demonstration of the transmissible agent in tissue from a pregnant woman with Creutzfeldt-Jakob disease. N Engl J Med 1993;327:649.
12. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994;35:513-29.
13. Kimberlin RH, Walker CA. Pathogenesis of experimental scrapie. In: Bock T, Marsh J, eds. Novel infectious agents and the central nervous system. Ciba Foundation Syposium 135. Chichester, UK: John Wiley & Sons, 1988:37-54.
14. Esmonde TF, Will RG, Slattery JM, et al. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993;341:205-7.
15. Heye N, Hensen S, Müller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994;343:298-9.
16. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using National Mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996;2:333-7.
17. Wientjens DP, Dayanipour Z, Hofman A, et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996;46:1287-91.
18. Brown P. Donor pool size and the risk of blood-borne Creutzfeldt-Jakob disease. Transfusion 1998;38:312-5.
19. Taylor DM, Dickinson AG, Fraser H, et al. Preparation of growth hormone free from contamination with unconventional slow viruses. Lancet 1985;2:260-2.
20. Pocchiari M, Peano S, Conz A, et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res 1991;35:161-6.
21. Klein MA, Frigg R, Flechsig E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997;390:687-90.